2026 Drug Price Projections: Rising Costs and Policy Implications
The upcoming year is expected to see an increase in drug prices in the United States, with at least 350 drugs projected to have higher costs in 2026. This analysis comes from health care research firm 3 Axis Advisors, indicating a rise in drug prices compared to the previous year. The median price hike is estimated to be around 4 percent. Despite drugmakers pledging to offer more favorable prices under new Trump administration policies, the number of drugs facing price increases is on the rise.
The Trump administration has successfully enforced its Most Favored Nation (MFN) policy on several drugmakers this year, ensuring that they offer their products at MFN pricing and provide direct-to-consumer (DTC) options. The DTC platform, TrumpRx, is set to launch early in 2026. President Trump hailed this as a significant victory for patient affordability in American health care, emphasizing the cooperation of pharmaceutical companies in reaching these agreements.
Pharmaceutical companies entered into voluntary agreements with the White House to avoid potential tariffs that could impact their profits. Despite these agreements, some of the drugs projected to cost more in 2026 are manufactured by companies that have agreed to Trump's MFN policy, such as Pfizer and GSK. The projected price increases for 2026 do not include rebates to pharmacy benefit managers and other discounts.
Critics of Trump's MFN policy argue that it fails to address the underlying issue of high drug costs, attributing the primary driver of exorbitant prices to patent monopolies. The MFN pricing deals and drug price negotiation do not directly tackle this root problem. While the pricing agreements apply to the Medicaid program, their impact on Medicaid patients may be minimal due to existing guarantees of the lowest price for commercial payers.
In conclusion, the analysis by 3 Axis Advisors suggests that drug prices in the U.S. are set to rise in 2026, despite efforts to negotiate more favorable pricing under the Trump administration. The ongoing debate surrounding high drug costs highlights the complexity of addressing affordability in the pharmaceutical industry.